VCP ScannerFree US Stock Screener & Financial AnalysisFree US Stock Screener
ScreenerThemes
DCF ValuationCalculate intrinsic value of US stocks
Market ValuationBuffett indicator, CAPE & macro gauges
Total ReturnSee dividends + price return history
DCA CalculatorSimulate recurring buys & compounding
Earnings
FAANG & Tech
AAPL vs MSFTNVDA vs AMDGOOGL vs META
Cloud & Cyber
CRM vs NOWCRWD vs PANWSNOW vs DDOG
Consumer & Auto
TSLA vs FAMZN vs WMTNFLX vs DIS
Finance & Crypto
JPM vs BACV vs MACOIN vs MSTR
Pharma & Energy
LLY vs NVOJNJ vs PFEXOM vs CVX
Compare Any Stocks...
WatchlistInsider
ScreenerThemes
Earnings
WatchlistInsider
STAASTAAR Surgical Company
$29.29$1.5B
Overview & Verdict
Overview
Valuation & Forecasts
Valuation ModelsEstimatesDCF Model
Price & Analyst Data
Analyst TargetsPrice HistoryTechnical Analysis
Financial Statements
Income StatementBalance SheetCash FlowRatios & Margins
Performance
P/E HistoryRevenue HistoryEarnings HistoryDividend HistoryTotal Return
Ownership
Holders
← Back to Screener
VCP ScannerFree US Stock Screener & Financial Analysis

Find stocks. Verify deeply. Act with conviction.

Data updated daily

Product

  • Screener
  • Themes
  • Valuation
  • Total Return
  • DCA Calculator
  • News
  • Earnings

Resources

  • Market Valuation
  • Compare
  • Insider Activity
  • Methodology
  • How It Works
  • Glossary
  • Learn

Get Ideas

Get weekly stock ideas — free

© 2026 VCP Scanner
AboutPrivacyTerms
Not financial advice. Do your own research.
ScreenerNewsCompareWatchlist
HomeStocksSTAACash Flow

STAAR Surgical Company (STAA) Cash Flow Statement

30Y historyFree accessUpdated daily

Cash generation remains highly inconsistent, highlighted by a 2026Q1 operating cash flow to net income ratio of -4.17, which suggests that non-cash charges like stock-based compensation continue to obscure underlying cash burn.

STAA Cash Flow Statement

Income StatementBalance SheetCash FlowRatios
AnnualQuarterly
MetricTTMJan'26Dec'24Dec'23Dec'22Dec'21Jan'21Jan'20Dec'18Dec'17Dec'16Jan'16Jan'15Jan'14Dec'12Dec'11Dec'10Jan'10Jan'09Dec'07Dec'06Dec'05Dec'04Jan'04Jan'03Dec'01Dec'00Dec'99Jan'99Jan'98Jan'97
Cash from Operations-50.19M-34.23M15.72M14.59M35.72M43.96M20.95M25.8M12.77M2.85M1.05M-2.16M-7.95M3.35M3.22M5.35M-4.42M1.43M-8.23M-11.18M-8.65M-6.98M-8.8M-4.15M569K-2.56M-5.37M4.9M4.3M7.6M8.5M
Operating CF Margin %--14.3%5.01%4.53%12.56%19.07%12.82%17.18%10.3%3.15%1.27%-2.8%-10.6%4.64%5.04%8.52%-8.04%1.89%-10.99%-18.84%-15.36%-13.6%-17.03%-8.22%1.18%-5.09%-9.95%8.31%7.93%17.88%20.14%
Operating CF Growth %-1179.81%-317.68%7.75%-59.14%-18.76%109.83%-18.78%102.04%347.49%171.97%148.52%72.81%-337.2%4.2%-39.82%221.03%-409.53%117.34%26.43%-29.34%-23.95%20.76%-112.35%-828.65%122.24%52.39%-209.64%13.95%-43.42%-10.59%70%
Net Income-21.03M-80.45M-20.21M21.35M39.01M27.51M5.91M14.05M4.97M-2.14M-12.13M-6.53M-8.39M398K-1.76M1.35M-4.11M-6.2M-23.2M-16M-15.04M-11.18M-11.33M-8.36M-17.16M-14.83M-18.9M2.2M4.1M7.4M6.9M
Depreciation & Amortization8.6M8.32M6.89M5.12M4.51M3.64M3.1M3.7M2.46M3.35M2.89M2.4M2.46M2.15M1.96M2.27M2.41M3.74M3.64M2.51M2.37M2.47M2.69M2.9M3.1M3.62M3.73M4.2M4.4M3.5M2.3M
Stock-Based Compensation24.57M30.59M27.21M23.52M20.37M14.61M12.15M10.55M6.76M3.16M8.56M3.3M4.66M4.49M3.21M1.91M1.25M1.46M1.51M000000000000
Deferred Taxes923K-2.92M3.59M3.26M-1.34M-1.51M-849K-3.48M441K-547K-1.36M473K-842K104K143K367K253K246K238K493K179K0009.29M-4.43M-6.63M0-300K3.3M0
Other Non-Cash Items25.16M26.55M3.64M2.18M2.3M2.11M3.41M2.23M2.62M3.01M918K478K379K608K94K67K421K990K5.38M1.79M1.47M850K1.08M1.35M1.7M13.13M22.5M-1.2M-100K200K-700K
Working Capital Changes-88.42M-16.33M-5.4M-40.84M-29.13M-2.39M-2.76M-1.25M-4.49M-3.99M2.17M-2.29M-6.22M-4.4M-426K-616K-4.63M1.19M4.19M-598K2.33M877K-1.25M-42K3.64M-41K-6.07M-300K-4M-7.1M0
Change in Receivables-42.26M27.83M16.49K-32.76M-19.6M-8.87M-3.97M-4.5M-6.04M-1.86M-771K-4.89M-934K-2.94M224K-435K-207K-944K-891K000000000000
Change in Inventory-6.59M-16.98M-10K-14.36M-7.94M66K-1.39M-950K-4.19M312K1.82M327K-3.94M-1.6M-1.02M-85K1.52M1.59M1.13M861K1.9M270K-2.28M-1.04M3.11M-1.32M-4.02M0-2.1M-2.3M0
Change in Payables-2.5M-5.51M75-701K1.8M108K-1.2M1.08M243K-2.5M1.01M14K972K407K1.01M480K-1.2M1.12M-1.87M000000000000
Cash from Investing13.13M46.34M-59.22M74.35M-156.38M-13.64M-8.4M-10.18M-2.25M-1.05M-3.21M-2.04M-4.05M-3.45M-2.19M-889K18.77M-7.61M1.12M-4.67M145K4.08M-7.29M2.15M-406K-687K-3.8M-10.7M-10.1M-7.4M-10.7M
Capital Expenditures-4.79M-5.82M-23.39M-18.19M-18.11M-13.64M-8.4M-10.1M-2.25M-1.05M-3.21M-2.04M-4.05M-3.45M-2.31M-962K-320K-586K-1.09M-691K-779K-1.19M-1.71M-1.31M-874K-1.18M-3.34M-5M-2M-2.8M-4.3M
CapEx % of Revenue1.65%2.43%7.45%5.64%6.37%5.92%5.14%6.72%1.81%1.15%3.89%2.65%5.41%4.77%3.62%1.53%0.58%0.78%1.46%1.16%1.38%2.33%3.3%2.59%1.81%2.35%6.19%8.47%3.69%6.59%10.19%
Acquisitions0000138.27M0000002K000011.82M205K2.21M000-16K00000000
Investments-------------------------------
Other Investing0198K00-138.27M00-83K0002K00125K73K7.4M-7.41M43K-3.98M1.07M146K-448K3.46M468K493K-460.51K-5.7M-8.1M-4.6M-6.4M
Cash from Financing-5.3M-4.55M5.72M7.42M8.3M17.79M19.57M149K74.64M2.44M2.95M4.58M2.53M2.45M4.32M2.77M-11.52M7.36M997K18.73M2.81M12.3M12.55M7.59M-592K-1.66M12.22M5.2M4.1M100K5M
Debt Issued (Net)0-42K-165K-161K-126K-1.65M-1.08M-3.31M-1.91M-1.3M1.12M-391K-490K-841K2.77M-575K-5.8M-1.15M957K1.54M-81K072K-2.91M-2.6M276K-8.98M4.1M3.9M-800K4.3M
Equity Issued (Net)-8.19M-2.99M-1.5M-2.1M1K1K1K2K-54K-234K-611K2K2K000-6.8M8.5M017.2M2.89M130K829K10.5M6K63K21.2M1.1M200K900K800K
Dividends Paid0000000000000000000000000000000
Share Repurchases-8.49M-6.46M-1.5M-2.1M0000-54K-234K-611K00000-6.8M0000000000-400K-200K-100K-300K
Other Financing2.89M-1.52M7.39M9.67M8.42M19.44M20.65M3.46M76.6M3.97M2.44M4.97M3.02M3.29M1.51M3.34M1.07M1K40K0-14K12.17M11.65M02M-2M0000-100K
Net Change in Cash-41.25M8.99M-38.88M96.56M-113.23M47.25M32.48M15.97M85.36M4.52M597K389K-9.94M1.28M5.09M7.21M3.05M1.34M-5.9M3.14M-4.95M8.52M-3.1M6.28M156K-5.23M2.74M-1.4M-1.5M-200K2.6M
Free Cash Flow-54.99M-40.05M-7.67M-3.59M17.61M30.32M12.55M15.62M10.52M1.81M-2.16M-4.21M-12.01M-96K906K4.38M-4.74M841K-9.32M-11.88M-9.43M-8.17M-10.51M-5.46M-305K-3.74M-8.71M-100K2.3M4.8M4.2M
FCF Margin %-18.94%-16.73%-2.44%-1.11%6.19%13.15%7.68%10.4%8.49%1.99%-2.62%-5.45%-16.01%-0.13%1.42%6.98%-8.62%1.12%-12.44%-20%-16.75%-15.93%-20.33%-10.81%-0.63%-7.44%-16.14%-0.17%4.24%11.29%9.95%
FCF Growth %-301.94%-422.23%-113.38%-120.41%-41.92%141.63%-19.66%48.42%482.29%183.81%48.73%64.97%-12405.21%-110.6%-79.33%192.55%-663.26%109.02%21.52%-25.98%-15.37%22.26%-92.65%-1688.52%91.84%57.09%-8611.68%-104.35%-52.08%14.29%180%
FCF per Share-1.08-0.81-0.16-0.070.360.610.260.330.230.04-0.05-0.11-0.32-0.000.020.12-0.140.03-0.32-0.42-0.37-0.34-0.54-0.31-0.02-0.22-0.57-0.010.160.340.30
FCF Conversion (FCF/Net Income)2.61x0.43x-0.78x0.68x0.90x1.60x3.54x1.84x2.57x-1.33x-0.09x0.33x0.95x8.42x-1.82x3.97x-83.34x-0.23x0.35x0.70x0.57x0.62x0.78x0.50x-0.03x0.17x0.28x2.23x1.79x1.03x1.23x
Interest Paid0087K75K52K75K0000000000000000000000000
Taxes Paid0010.98M2.84M6.63M7.47M0000000000000000000000000

Key Metrics

Growth RegimeMixed
ProfitabilityNegative
Balance SheetHealthy
Cash FlowBurning
Top Statement Risk

Geographic revenue concentration risk

Verified Source

Metrics are mathematically derived from official filings.

SEC 10-K (2026Q1)

Earnings Quality Lacks Cash Support

As reported in recent financial statements, STAA's operating cash flow frequently diverges from net income, with the 2026Q1 OCF/NI ratio of -4.17 highlighting a significant disconnect between accounting profitability and actual cash generation, suggesting that accruals and working capital swings are masking underlying operational cash volatility.

The persistent gap between net income and operating cash flow suggests that reported earnings are not translating into liquidity, likely due to aggressive revenue recognition or inventory build-ups. Investors should monitor whether this divergence is a temporary byproduct of expansion or a structural issue where earnings quality remains perpetually compromised by non-cash adjustments.

Free Cash Flow Volatility Persists

Based on the company's quarterly filings, the free cash flow trajectory has been highly erratic, swinging from a positive $28.9 million in 2023Q4 to a negative $22.1 million in 2026Q1, indicating that the business lacks the consistent cash-generating maturity required to fund its own operational growth.

The inability to maintain positive FCF margins suggests that the company's current business model is highly sensitive to volume fluctuations and external demand shocks. This volatility implies that the company remains in a capital-intensive growth phase that may require further liquidity if revenue trends do not stabilize.

Working Capital Swings Impair Liquidity

According to recent SEC filings, STAA's working capital dynamics have become increasingly erratic, evidenced by a $42.7 million outflow in 2026Q1, which suggests that the company is struggling to manage its inventory and receivables cycle effectively amidst shifting global demand for its refractive lens products.

The significant quarterly fluctuations in working capital suggest that the company's consignment model and distributor relationships in China may be creating lumpy cash flows. This instability warrants further investigation into whether inventory is accumulating in the channel, potentially creating future air pockets in revenue recognition.

SBC Masks True Cash Burn

As evidenced by the provided financial data, stock-based compensation remains a consistent feature of the company's cost structure, with quarterly charges often exceeding $7 million, which obscures the true extent of the company's cash burn by artificially inflating the reported net income figures in recent periods.

While SBC is a non-cash expense, its consistent scale suggests that the company's reported profitability is significantly flattered. Analysts should adjust for these charges to understand the true cash-based cost of operations, which appears to be significantly higher than the headline figures suggest.

STAA — Frequently Asked Questions

Quick answers to the most common questions about buying STAA stock.

How much cash does STAAR Surgical Company (STAA) generate from operations?

STAAR Surgical Company (STAA) generated $-34.2M in net cash from operating activities in 2025. This reflects the cash generated directly from core business operations.

What is STAAR Surgical Company's free cash flow?

STAAR Surgical Company (STAA) reported negative free cash flow of $40.0M in 2025, indicating capital requirements exceeded cash from operations.

What is STAAR Surgical Company's capital expenditure (CapEx)?

STAAR Surgical Company (STAA) spent $5.8M on capital expenditures in 2025. CapEx represents the cash invested in physical assets like property, plant, and equipment to maintain or grow the business.

How does STAAR Surgical Company distribute cash to shareholders?

In 2025, STAAR Surgical Company (STAA) spent $6.5M on share repurchases. This shows the company's commitment to returning capital to its equity investors.